• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

    10/2/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email

    SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced that the first patient was treated with [212Pb]PSV359 in a second cohort of the Company's Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359.

    Patients in this cohort are receiving [212Pb]PSV359 at 5.0 mCi for up to four doses every eight weeks. The Safety Monitoring Committee (SMC) recommended evaluating [212Pb]PSV359 at a higher dose based on its review of two patients dosed with [212Pb]PSV359 at 2.5 mCi alone.

    "Dosing the first patient in the second cohort marks an important step in advancing our evaluation of [212Pb]PSV359 for cancers expressing FAP-α," said Markus Puhlmann, Chief Medical Officer of Perspective. "FAP-α is found in a wide range of epithelial malignancies, including pancreatic cancer, colorectal cancer, and many sarcomas. Because of its multi-factorial biologic effects within the tumor microenvironment, it contributes to disease progression and negatively affects treatment response. These characteristics highlight the broad potential of PSV359 across multiple solid tumors. This study is helping us determine the optimal dose and indications to move forward, either as a monotherapy or in future combination strategies."

    About PSV359

    PSV359 was designed to target and deliver 212Pb to tumor sites expressing FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. The targeting moiety may also be radiolabeled with 203Pb or 68Ga (known as PSV377) to detect FAP-α expression in individual patients. Preclinical imaging and therapy as well as human imaging results suggest Perspective's proprietary targeting ligand has improved levels of target engagement and uptake in tumors, as well as reduced retention in healthy tissues, which may result in a desirable therapeutic index.

    Perspective is conducting a multi-center, open-label, dose-finding and dose-expansion study (clinicaltrials.gov identifier NCT06710756) of [212Pb]PSV359 in patients with advanced solid tumors that express FAP-α as determined by imaging with [203Pb]PSV359. The primary objective of the dose finding phase of the study is to assess the safety and tolerability of various doses of [212Pb]PSV359 in order to determine the recommended Phase 2 dose to be used in the expansion phase of the study, where anti-tumor activities may be an additional primary outcome measure.

    About FAP-α

    FAP-α is a protein abundantly expressed on the surface of cancer-associated fibroblasts (CAFs) in the stroma, a part of the tumor microenvironment (TME) in the majority of epithelial cancers. In addition to expression on CAFs, FAP-α is expressed on certain cancer cells themselves, including sarcomas and mesotheliomas.1,2,3,4 Higher FAP-α expression has been found to be associated with poor prognosis in a number of solid tumors such as colorectal cancer, pancreatic cancer, stomach cancer, mesothelioma, head and neck cancer, esophageal cancer, and ovarian cancer.5,6,7,8,9 Expression of FAP-α in healthy tissues is usually low.3,4

    About Perspective Therapeutics, Inc.

    Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

    The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

    For more information, please visit the Company's website at www.perspectivetherapeutics.com.

    Safe Harbor Statement

    This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's plans to select patients for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359 and the ability of the targeting moiety to be radiolabeled with 68Ga as well to detect FAP-α expression in individual patients; expectations regarding the advancement of and learnings from the Company's clinical development programs, including the potential of [212Pb]PSV359 to treat a variety of malignancies; the Company's goal of selecting a dose for [212Pb]PSV359 to advance as either a monotherapy or in combination with other agents for a variety of indications for future clinical development; the ability of the Company's discovery team to create novel radiopharmaceuticals to provide innovative therapies for cancer patients in need of new treatment options; the Company's expectation that certain characteristics of PSV359 identified in preclinical research, such as preferential uptake and retention in the tumor, binding affinity to FAP-α and fast clearance from healthy tissues, will translate into the clinic; the Company's plans to assess the safety and tolerability of various doses of [212Pb]PSV359 to determine the recommended Phase 2 dose to be used in the expansion phase of the study, and its belief that anti-tumor activity may be an additional primary outcome measure of the expansion phase of the study; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the opportunity to personalize treatment and optimize patient outcomes using the Company's complementary imaging diagnostics that incorporate the same targeting moieties; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; the Company's expectations, beliefs, intentions, and strategies regarding the future; and other statements that are not historical fact.

    The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, in the Company's other filings with the Securities and Exchange Commission (the "SEC"), and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

    Media and Investor Relations Contacts:

    Perspective Therapeutics IR:

    Annie J. Cheng, CFA

    [email protected]

    Russo Partners, LLC

    Nic Johnson

    [email protected]


    1 Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235-7239. doi:10.1073/pnas.87.18.7235

    2 Dziadek S, Kraxner A, Cheng WY, et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Front Immunol. 2024;15:1352615. Published 2024 Mar 15. doi:10.3389/fimmu.2024.1352615

    3 Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805. doi:10.2967/jnumed.119.227967

    4 Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783-803. doi:10.1007/s10555-020-09909-3

    5 Coto-Llerena M, Ercan C, Kancherla V, et al. High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Front Oncol. 2020;10:979. Published 2020 Jul 8. doi:10.3389/fonc.2020.00979

    6 Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736-1741. doi:10.1158/1078-0432.CCR-06-1746

    7 Wang S, Zheng Y, Yang F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6(1):249. Published 2021 Jul 5. doi:10.1038/s41392-021-00659-4

    8 Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154-158. doi:10.1097/MPA.0b013e31816618ce

    9 Ma C, Xi S, Sun, H, et al. Identifying the oncogenic roles of FAP in human cancers based on systematic analysis. Aging 2023;15(14):7056-7083. doi: 10.18632/aging.204892



    Primary Logo

    Get the next $CATX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    7/25/2024$24.00Buy
    BofA Securities
    5/9/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CATX
    SEC Filings

    View All

    Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    10/1/25 7:15:18 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/4/25 7:04:41 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    9/3/25 7:04:59 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Sendek Joel

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:06:51 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Sendek Joel

    3 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:05:22 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Martinez Maria E

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:04:08 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 6:44:41 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 5:04:49 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 5:03:59 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

    3/13/25 7:26:51 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Scotiabank initiated coverage on Perspective Therapeutics with a new price target

    Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00

    3/7/25 8:03:16 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

    11/25/24 7:39:30 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

    SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced that the first patient was treated with [212Pb]PSV359 in a second cohort of the Company's Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359. Patients in this cohort are receiving [

    10/2/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

    First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with previously treated, histologically confirmed metastatic melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. Patients in this cohort are recei

    9/15/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $CATX
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

     Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject

    5/30/25 5:21:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

      Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

    1/24/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

    SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will

    1/22/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 4:05:13 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/7/24 9:24:55 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care